Aegerion Pharmaceuticals Tumbles After a Big Earnings Miss

Aegerion just reported its first-quarter earnings and missed analyst estimates. What went wrong?

May 7, 2014 at 12:04PM

Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) are down nearly 27% as of this writing after the company reported lackluster first-quarter earnings and lowered its full-year guidance last night.

Aegerion reported net product sales of $27 million, up from $1.2 million in the prior-year quarter, but missing the consensus estimate of $33.6 million. It reported a GAAP net loss of $0.54 per share, up from a net loss of $0.64 per share a year earlier. Analysts had anticipated a narrower loss of $0.35 per share.

AEGR Chart

Source: Ycharts.

Looking ahead into the rest of fiscal 2014, Aegerion expects net product sales between $180 million to $200 million, revised downwards from its prior forecast of $190 million to $210 million. On the bright side, the company expects to achieve positive cash flow operations by the second half of the year. Aegerion finished the quarter with $117 million in cash and equivalents -- a 7% decrease from the first quarter of 2013.

A matter of trust
Aegerion has fallen more than 40% during the past six months due to concerns regarding its only marketed product, Juxtapid. The drug is one of the most expensive drugs in the world at nearly $300,000 per patient per year, and is a treatment for homozygous familial hypercholesterolemia (HoFH). HoFH is an extremely rare, inherited lipid disorder which only affects only one in a million people worldwide. Juxtapid was approved in the U.S. in December 2012, and in Europe in August 2013 as Lojuxta.

Aegerion started its dive last November after receiving a subpoena from the Department of Justice regarding its marketing practices and a warning letter from the FDA about some public comments CEO Marc Beer had made. There have also been questions regarding Aegerion's broad claim that Juxtapid could treat 300 to 3,000 HoFH patients in the U.S., because HoFH's one-in-a-million ratio suggests that there may be closer to 300 potential patients instead of 3,000.

Positive overseas catalysts
Despite Aegerion's unresolved issues in the U.S., which accounts for 96% of Juxtapid sales, the company recently reported several positive developments in foreign countries. Aegerion gained approval for Juxtapid in Mexico in January, in Canada in February, and initiated a phase 3 trial for the drug in Japan in April. Aegerion also reported robust demand for the drug in Brazil, although sales were adversely affected by pricing issues, order delays, and an anti-corruption investigation regarding prescriptions.

Expanding Juxtapid's overseas presence could give Aegerion an edge against its primary competitor in HoFH treatments, Sanofi (NYSE:SNY) and Isis Pharmaceuticals' (NASDAQ:ISIS) Kynamro. Kynamro is considered a major threat to Juxtapid due to its much lower price tag of $176,000 per year.

The FDA approved Kynamro last January, although the Committee for Medicinal Products for Human Use (CHMP) in Europe issued a negative opinion of the drug last March due to safety concerns. Sanofi markets Kynamro in the U.S. and shares the profits with Isis. Isis gets a 30% cut of the profits, which could rise to 50% if revenue hits $2 billion annually.

However, neither Juxtapid nor Kynamro are expected to hit $2 billion in sales. Aegerion expects Juxtapid to potentially generate peak sales of $1 billion. Analysts expect Juxtapid to generate peak sales around $400 million -- which is the similar to the average estimate for Kynamro.

A matter of expenses
During the first quarter, Aegerion's expenses rose across the board. Selling, general, and adminstrative expenses rose 141% year-over-year to $31.8 million. The company attributed that increase the commercial launch of Juxtapid in the U.S., its global expansion, and an increased headcount as a result of both. Higher legal fees were also a factor. Research and development expenses climbed 36% to $7.9 million, due to higher expenses related to its development program for an indication for pediatric HoFH.

Looking ahead to the full year, management expects Aegerion's total GAAP operating expenses will be between $185 million to $195 million. Since the company expects net product sales of $180 million to $200 million for the year, Aegerion could possibly squeeze out a small profit by the end of the year.

The bottom line
In conclusion, there's a lot of drawbacks and few benefits to investing in Aegerion. The company's statements and marketing practices face scrutiny back at home, expenses are rising, and its top- and bottom-line growth are falling short of expectations. While Aegerion certainly has opportunities in overseas expansion, its could easily lose its early lead if Kynamro gains approval in additional markets.

Is this top stock a better pick than Aegerion?
Give me five minutes, and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer handpicks one stock with outstanding potential. But it's not just any run-of-the-mill company; it’s a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% during the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information